Inactive

This is a combined synopsis/solicitation for commercial items and services prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 as supplemented with additional i... This is a combined synopsis/solicitation for commercial items and services prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; Quotes are being requested and a written solicitation will not be issued. This acquisition is for a commercial item or service and is conducted under the authority of the FAR Part 13.5—Simplified Acquisition Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items. The mission of the National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) is to conduct state-of-the-art research on basic mechanisms that underlie substance use disorders (SUDs), and to develop new methods for the treatment of SUDs. Research is supported at the molecular, genetic, cellular, animal, and human clinical levels and conceptually integrates highly innovative strategies and techniques. The long-term goal of the research is to better understand the biological and behavioral factors contributing to initiation, maintenance, and elimination of SUDs (and associated diseases), and to translate this knowledge into improved strategies for prevention, treatment, and reduction of negative consequences for the individual and for society caused by substance use disorders. Using volunteer human participants, the IRP clinical program conducts residential and nonresidential research studies that interrelate with pre-clinical laboratory work. In general, these studies include assessment of drug-use patterns, investigation of underlying brain mechanisms, and testing of a variety of SUD behavioral or biomedical treatments. NIDA requires the services necessary to develop, implement, monitor and assess grassroots outreach and community partnership campaigns in order to recruit eligible research participants for inclusion in human research studies conducted by the NIDA IRP as part of their ongoing mission. NIDA IRP enrolls a highly targeted and representative study population of research participants including those with active SUDs (e.g. nicotine, alcohol, cocaine, marijuana, opioids) who are not seeking treatment, those who are seeking treatment, people who use these substances occasionally and healthy controls who match the other populations with respect to characteristics such as age, gender, socio-economic status (SES), IQ, etc. The NIDA IRP is also conducting studies requiring HIV-positive populations. The Contractor shall protect the sensitive nature of the information and data collected when working with these populations. NIDA requires the services necessary to develop, implement, monitor and assess grassroots outreach and community partnership campaigns in order to recruit eligible research participants for inclusion in human research studies conducted by the NIDA IRP as part of their ongoing mission. NIDA IRP enrolls a highly targeted and representative study population of research participants including those with active SUDs (e.g. nicotine, alcohol, cocaine, marijuana, opioids) who are not seeking treatment, those who are seeking treatment, people who use these substances occasionally and healthy controls who match the other populations with respect to characteristics such as age, gender, socio-economic status (SES), IQ, etc. The NIDA IRP is also conducting studies requiring HIV-positive populations. Special attention and consideration needs to be made to the sensitive nature of the data collected when working with these populations. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2020-04, dated 01-15-2020. NAICS Code: The associated NAICS code 541613, and the small business size standard $16,500,000. This requirement is not a total small business set-aside. PLEASE REFER TO THE ATTACHMENTS FOR THE ENTIRE COMBINED SYNOPSIS /SOLICITATION DOCUMENTS, INSTRUCTIONS AND SOLICITATION ATTACHMENTS. Questions and requests for clarification should be submitted electronically to the Contracting Officer, Josh Lazarus at Josh.Lazarus@nih.gov on or before 3:00 pm July 30, 2020. Any questions or request for clarification must include the combined synopsis/solicitation 75N95020Q00126 and the Title in the Subject Line. When submitting quotes, in addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. The Offeror must submit with their Quote the following information: Technical Quote in accordance with this combined synopsis/solicitation in a searchable PDF format; Business Quote in an Searchable PDF or Word Document; Cost/Price Data and Tables in an Excel format; Dun and Bradstreet Number (DUNS); and Verification of System for Award Management (SAM) Registration www.sam.gov. Technical Quotes shall be submitted in accordance with the General Requirement identified in Section 6 of the attached combined synopsis/solicitation. The response to the combined synopsis/solicitation is DUE NO LATER THAN August 13, 2020 at 3:00 P.M. Eastern Standard Time (EST). Offers submitted after the deadline may not be considered. The response should be submitted in a searchable electronic format to the Contracting Officer, Josh Lazarus at Josh.Lazarus@nih.gov. Electronic submittals must include the combined synopsis/solicitation 75N95020Q00126 and the Title in the Subject Line.